Best Practice Approaches for Understanding Chronic Obstructive Pulmonary Disease and Precision Medicine Treatment

Program Description

Precision medicine in chronic obstructive pulmonary disease (COPD) aims to tailor treatment based on individual characteristics, such as phenotype, biomarkers, and treatable traits, to personalize care and improve outcomes. Despite advances, managing COPD remains challenging due to its heterogeneity and progression. Precision medicine, especially for type 2 inflammation, is transforming treatment by targeting the right therapy to the right patient. Chronic disease state management is a part of the pharmacist’s evolving clinical role, which includes COPD, and pharmacists should be able to support precision medicine treatment strategies to assess drug appropriateness, increase adherence, and reduce exacerbations and hospitalizations. This activity will address the inflammatory processes of COPD and strategies using phenotyping, biomarkers, and treatable traits to provide treatment of COPD and bring attention to the health disparities and the impact they have on quality of life for patients living with COPD. With a greater understanding of precision medicine treatment strategies for COPD, pharmacists will be better equipped to contribute to clinical decision-making in COPD teams and manage and assess appropriate therapies for individual patients to help reduce implications of COPD on public health.

Target Audience: Ambulatory Care Pharmacist, Community Pharmacist, Consultant Pharmacist, Health System Pharmacist, Retail Pharmacist

Type of Activity: Application
Release date: December 5, 2025
Expiration date: December 5, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify healthcare disparities and highlight the clinical and economic burden of chronic obstructive pulmonary disease (COPD).
• Analyze the inflammatory process and key type 2 inflammation characteristics. 
• Explore precision medicine treatment strategies, including phenotyping, biomarkers, and treatable traits for patients with COPD. 

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-394-H01-P. The activity is available for CE credit through December 5, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Jessica L. Wallace, PharmD, BCPS

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms